Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 1998

View Archived Issues

Company Profile: ArQule

Company Profile: Avax Technologies

Cytogen: Q4 and year-end 1997 highlights

Cholera toxin enhances transcutaneous delivery, enabling development of needle-free vaccines

Acetaminophen increases risk of hemorrhage in combination with warfarin

Anika: year-end 1997 highlights

ArQule and Sepracor to optimize lead antiinfective compounds

Phase I results reported for alpha-gal in Fabry's disease

Status of Oncolym updated

J&J to withdraw from pramlintide collaboration; exendin update

Cell Therapeutics: Q4 and year-end 1997 highlights

University of Alabama describes delta-EKLFs for hemoglobinopathies

3-D reveals new trypsin-like serine protease inhibitors

Vaccines for group B meningococcal infection disclosed

Kowa product pipeline in review

Antidiabetic agents in development at Boehringer Mannheim

DiagnoCure signs agreements related to development of targeted nanoerythrosomes

More light shed on Lp(a) and its role in heart disease

Flavonoid intake reduces risk of death from CHD

Searle uses Epimmune technologies to develop cancer therapies

More on anti-HIV research at Glaxo Wellcome

BOPP will enter clinical testing in cancer patients

Gliadel Wafer approved for marketing in Brazil

Distribution and marketing of terfenadine-containing products discontinued in U.S.

Watson acquires Hoechst Marion Roussel's U.S. generic drug subsidiary

Efficacy of immunoliposomal amphotericin B confirmed in mice with invasive aspergillosis

Liposomal ciprofloxacin formulations demonstrate high efficacy and versatility

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...